ESTRO 2023 - Abstract Book

S136

Saturday 13 May

ESTRO 2023

SP-0177 The access gap M.L. Yap 1,2,3

1 UNSW Sydney, Collaboration for Cancer Outcomes, Research and Evaluation (CCORE), Liverpool, Australia; 2 Western Sydney University, Liverpool and Macarthur Cancer Therapy Centres,, Campbelltown, Australia; 3 UNSW Sydney, The George institute for Global Health, , Newtown, Australia Abstract Text Radiation therapy is an evidence based, cost-effective component of comprehensive cancer care. It has been estimated that 1 in 2 people diagnosed with cancer should receive radiation therapy as part of their management. However, even in high income countries with universal health care, there is a clear access gap, with population-based data from a number of jurisdictions demonstrating that ~ 1 in 3 people diagnosed with cancer actually access radiation therapy. In low- and middle-income countries globally, the access gap is even more pronounced. This talk will outline equity issues resulting in this access gap, including the existing barriers for vulnerable populations within well-resourced settings. It will also outline how patient referral pathways contribute to the access gap. Current and future solutions, including advocacy, education, policy changes and culturally specific initiatives will be discussed.

SP-0178 The outcomes gap A.Aggarwal United Kingdom

Abstract not available

Award Lecture: E van der Schueren Award

SP-0180 Medical education in the post-COVID era: Challenges and opportunities L.T. Tan 1 1 Cambridge University Hospitals NHS TRust, Oncology, Cambridge, United Kingdom

Abstract Text The traditional model for medical education is the lecture delivered by an expert, the so-called “sage on the stage”. Despite increasing evidence that this model may have limited impact as an educational tool, it remains the most prevalent strategy in oncology postgraduate education, not least because of its overwhelming popularity with both students and teachers. The COVID pandemic has challenged thinking on all aspects of life necessitating radical changes in many circumstances previously considered sacrosanct. This lecture discusses some of the changes that have been implemented in oncology education as a result of the pandemic and explores the pros and cons of alternative educational strategies to the traditional model. SP-0182 Quo Vadis? from pioneering experiences to digital medicine in the treatment of rectal cancer V. Valentini 1 1 Fondazione Policlinico Universitario A.Gemelli IRCCS - Università Cattolica S.Cuore, Radiology, Radiation Oncology and Haematology Department , Rome, Italy Abstract Text We can distinguish different historical periods since the 1970s in the treatment of rectal cancer with regard to the integration of radiotherapy with surgery and chemotherapy, in which the doses, volumes, fractionations, and timing used have changed according to evidence from the literature and improvements in the technologies and procedures of the various disciplines. The following periods can be identified: pioneering, which runs from the 1970s to the mid-1980s in which there were few centers in the world in which radiotherapy was used in the integrated treatment of rectal cancer; proof-of-concept, up to the mid-1990s in which the first benefit studies, mainly single-center, appeared; consolidated evidence, from the mid 1990s to 2010, in which the main evidences were consolidated through cooperative studies, which still constitute the reference of the treatment of rectal cancer; emerging questions, from 2010 to the present time, in which the issues of reduction and intensification of combination therapies based on risk factors, the arrival of molecular profiles, and digital modeling are being addressed. For each of these periods, the salient features of radiotherapy modalities and the main evidence of clinical benefits for patients will be analyzed, also drawing on the 40-year experience of their center. Award Lecture: Jens Overgaard Legacy Award

Symposium: Dose escalation

SP-0183 Dose escalation: Biological or absolute - The evidence I.R. Vogelius Denmark

Abstract not available

SP-0184 What can IMRT achieve in dose escalation? L. Kerkmeijer